1.
Michiels JJ, Prins ME, Hagemeijer A, Brederoo P, van der Meulen J, van Vliet HH, Abels J: Philadelphia chromosome-positive essential thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 1987;88:645-652.
2.
Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, Ridell B, Fernando P, Zanetto U: Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004;83:504-512.
3.
Georgii A, Vykoupil KF, Buhr H, Choritz H, Doehler U, Kaloutsi V, Werner M: Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 1990;186:3-27.
4.
Georgii A, Buesche G, Kreft A: The histopathology of chronic myeloproliferative diseases. Bailliere's Clin Haematol 1998;11:721-749.
5.
Thiele J, Kvasnicka HM, Deihl V, Fischer R, Michiels JJ: Clinicopathological diagnosis and differential criteria of thrombocythemia in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leukemia Lymphoma 1999;33:207-218.
6.
Michiels JJ, Thiele J: Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-145.
7.
Mason JE Jr, DeVita VT, Canellos GP: Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974;44:483-487.
8.
Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HAM, van Vliet HHDM: Platelet-mediated erythromelalgic, cerebral, ocular, and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528-544.
9.
Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, van Vliet HHDM: Platelet-mediated thrombotic complications in patients with ET: reversal by aspirin, platelet reduction, and not by coumadin. Blood Cells Mol Dis 2006;36:199-205.
10.
Michiels JJ, Ten Kate FWJ, Koudstaal PJ, Van Genderen PJJ: Aspirin responsive platelet thrombophilia in essential thrombocythemia and polycythemia vera. World J Hematol 2013;2:20-32.
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.